Keywords: AstraZeneca, Investment, Russia,Pharmastandards, AVVA Pharma, Contract manufacturing, Distribution

AstraZeneca to invest $1.2 billion in Russia by 2017; Pharmstandard deal with AVVA

Article | 28 December 2012

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) plans to invest up to $1.2 billion in its development in Russia during the 2012-2017 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in